Lazaridou Maria-Filothei, Gonschorek Evamaria, Massa Chiara, Friedrich Michael, Handke Diana, Mueller Anja, Jasinski-Bergner Simon, Dummer Reinhard, Koelblinger Peter, Seliger Barbara
Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Institute of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Oncoimmunology. 2020 Jun 3;9(1):1774323. doi: 10.1080/2162402X.2020.1774323.
Tumor escape is often associated with abnormalities in the surface expression of the human leukocyte antigen class I (HLA-I) antigens thereby limiting CD8 cytotoxic T cell responses. This impaired HLA-I surface expression can be mediated by deficient expression of components of the antigen processing and presentation machinery (APM) due to epigenetic, transcriptional and/or post-transcriptional processes. Since a discordant mRNA and protein expression pattern of APM components including the peptide transporter associated with antigen processing 1 (TAP1) has been frequently described in tumors of distinct origin, a post-transcriptional control of APM components caused by microRNAs (miR) was suggested. Using an approach, miR-200a-5p has been identified as a candidate miR binding to the 3' untranslated region (UTR) of TAP1. Luciferase reporter assays demonstrated a specific binding of miR-200a-5p to the TAP1 3'-UTR. Furthermore, the miR-200a-5p expression is inversely correlated with the TAP1 protein expression in HEK293T cells and in a panel of melanoma cell lines as well as in primary melanoma lesions. High levels of miR-200a-5p expression were associated with a shorter overall survival of melanoma patients. Overexpression of miR-200a-5p reduced TAP1 levels, which was accompanied by a decreased HLA-I surface expression and an enhanced NK cell sensitivity of melanoma cells. These data show for the first time a miR-mediated control of the peptide transporter subunit TAP1 in melanoma thereby leading to a reduced HLA-I surface expression accompanied by an altered immune recognition and reduced patients' survival.
Ab: antibody; ACTB: β-actin; APM: antigen processing and presentation machinery; ATCC: American tissue culture collection; β-m: β-microglobulin; BSA: bovine serum albumin; CTL: cytotoxic T lymphocyte; FCS: fetal calf serum; FFL: firefly luciferase; FFPE: formalin-fixed paraffin-embedded; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HC: heavy chain; HLA: human leukocyte antigen; HLA-I: HLA class I; HRP: horseradish peroxidase; IFN: interferon; im-miR: immune modulatory miRNA; LMP: low molecular weight protein; luc: luciferase; MFI: mean fluorescence intensity; MHC: major histocompatibility complex; miR: microRNA; NC: negative control; NK: natural killer; NSCLC: non-small cell lung carcinoma; OS: overall survival; PBMC: peripheral blood mononuclear cells; RBP: RNA-binding proteins; RL: Renilla; RLU: relative light units; TAP: transporter associated with antigen processing; tpn: tapasin; UTR: untranslated region.
肿瘤逃逸通常与人类白细胞抗原I类(HLA-I)抗原的表面表达异常相关,从而限制CD8细胞毒性T细胞反应。这种HLA-I表面表达受损可由抗原加工和呈递机制(APM)成分因表观遗传、转录和/或转录后过程导致的表达缺陷介导。由于在不同起源的肿瘤中经常描述包括与抗原加工相关的肽转运体1(TAP1)在内的APM成分的mRNA和蛋白质表达模式不一致,因此有人提出由微小RNA(miR)对APM成分进行转录后调控。采用一种方法,已鉴定出miR-200a-5p是与TAP1的3'非翻译区(UTR)结合的候选miR。荧光素酶报告基因检测证明miR-200a-5p与TAP1 3'-UTR特异性结合。此外,miR-200a-5p表达与HEK293T细胞、一组黑色素瘤细胞系以及原发性黑色素瘤病变中的TAP1蛋白表达呈负相关。miR-200a-5p高表达与黑色素瘤患者较短的总生存期相关。miR-200a-5p过表达降低了TAP1水平,这伴随着HLA-I表面表达降低以及黑色素瘤细胞对NK细胞敏感性增强。这些数据首次表明miR介导黑色素瘤中肽转运体亚基TAP1的调控,从而导致HLA-I表面表达降低,同时伴有免疫识别改变和患者生存期缩短。
Ab:抗体;ACTB:β-肌动蛋白;APM:抗原加工和呈递机制;ATCC:美国组织培养物收藏中心;β-m:β-微球蛋白;BSA:牛血清白蛋白;CTL:细胞毒性T淋巴细胞;FCS:胎牛血清;FFL:萤火虫荧光素酶;FFPE:福尔马林固定石蜡包埋;GAPDH:甘油醛-3-磷酸脱氢酶;HC:重链;HLA:人类白细胞抗原;HLA-I:HLA I类;HRP:辣根过氧化物酶;IFN:干扰素;im-miR:免疫调节性微小RNA;LMP:低分子量蛋白质;luc:荧光素酶;MFI:平均荧光强度;MHC:主要组织相容性复合体;miR:微小RNA;NC:阴性对照;NK:自然杀伤细胞;NSCLC:非小细胞肺癌;OS:总生存期;PBMC:外周血单个核细胞;RBP:RNA结合蛋白;RL:海肾荧光素酶;RLU:相对光单位;TAP:与抗原加工相关的转运体;tpn:塔帕辛;UTR:非翻译区